Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Use of Antiemetic Agents in Acute Gastroenteritis 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity 5. Medicare pay-for-reporting effort draws fire from frustrated doctors
Your Article Summary
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal and gastrointestinal origin shows acceptable morbidity and high survival
European Journal of Surgical Oncology, 07/01/09
Hagendoorn J et al. - In a study to examine the use of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal carcinomatosis of colorectal and gastrointestinal origin, it was concluded that in well-selected pts referred to a specialized institution, CS–HIPEC has acceptable morbidity and high survival rate.
Methods- 67 pts underwent a laparotomy.
- Complete cytoreduction could be performed in 49 pts, who underwent 53 CS–HIPEC procedures.
- All had peritoneal carcinomatosis originating from primary colorectal, cecal, appendiceal, and gastric tumors.
- In pts who underwent CS–HIPEC, an R0 resection could be achieved in 4%, R1 in 88%, and R2 in 8%.
- 30-day mortality was 0; 1 pt died in-hospital after 10 wks.
- Median hospital stay was 12 days.
- Overall morbidity was 43%, including extended gastroparesis (11%), anastomotic failure (11%), and intra-abdominal abscess (9%).
- Mean time to clinical recurrence was 12 mos.
- Actuarial 1-yr survival was 88% and 2-yr survival was 75%.
Today in Colorectal Cancer/Polyps...keeping you current
Receive free subspecialty "5-minute updates" via email
Surgical management of colorectal liver metastases
Community Oncology , 10/09/09
Extended lymphadenectomy versus conventional surgery for rectal cancer: a meta-analysis : The Lancet Oncology
The Lancet Oncology - Online First, 10/23/09
A randomized trial on folic acid supplementation and risk of recurrent colorectal adenoma
American Journal of Clinical Nutrition, 10/29/09
Today in GI Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Surgical management of colorectal liver metastases
Community Oncology , 10/09/09
Treatment of Barretts esophagus with high-grade dysplasia and intramucosal adenocarcinoma
Expert Review of Gastroenterology & Hepatology, 10/13/09
Novel agents for the treatment of adenocarcinoma of the pancreas
Expert Review of Anticancer Therapy, 10/22/09
Sponsor
Article Search
Sponsor


See Latest Articles


